Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data from peripheral blood mononuclear cells in multiple sclerosis patients and controls

ABSTRACT: Multiple sclerosis (MS) is a neurodegenerative disease with a presumed autoimmune component. Expression profiling in immune cells can therefore be used in order to identify genes and pathways involved in MS pathogenesis. We conducted a genome-wide expression study in peripheral blood mononuclear cells (PBMC) from 12 MS patients and 15 controls in order to identify differentially expressed genes and pathways in MS.

ORGANISM(S): Homo sapiens

PROVIDER: GSE21942 | GEO | 2011/07/01

SECONDARY ACCESSION(S): PRJNA127227

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Expression data from peripheral blood mononuclear cells in multiple sclerosis patients and controls

Project description:Multiple sclerosis (MS) is a neurodegenerative disease with a presumed autoimmune component. Expression profiling in immune cells can therefore be used in order to identify genes and pathways involved in MS pathogenesis. We conducted a genome-wide expression study in peripheral blood mononuclear cells (PBMC) from 12 MS patients and 15 controls in order to identify differentially expressed genes and pathways in MS. PBMCs were isolated from whole blood and total RNA was extracted.

2011-07-01 | E-GEOD-21942 | biostudies-arrayexpress

Autoantibodies as diagnostic biomarkers for the detection, subtyping, and progression of Multiple Sclerosis

Project description:Human serum samples from Multiple Sclerosis (MS) subjects and healthy control subjects were probed onto human protein microarrays in order to identify differentially expressed autoantibody biomarkers that could be used as diagnostic indicators. Other neurodegenerative and non-neurodegenerative diseases were also used to help measure the specificity of the selected biomarkers.

2017-07-26 | GSE95718 | GEO

Expression profiles of PBMC from multiple sclerosis patients

Project description:Affymetrix GeneChip Human Gene 1.0 ST Array was applied to compare the expression profiles in peripheral blood mononuclear cells(PBMC) between healthy controls and multiple sclerosis patients(MS pt). It suggested that certain genes involved in apoptosis pathway have been changed regulated in PBMC from MS pt. Applying Affymetrix GeneChip Human Gene 1.0 ST Array and the mixed effects model for gene set analysis, we compared gene expression profiles between 8 multiple sclerosis (MS) patients and 4 healthy controls (HC).

2011-03-01 | E-GEOD-23832 | biostudies-arrayexpress

Expression profiles of PBMC from multiple sclerosis patients

2011-03-01 | GSE23832 | GEO

Peripheral blood gene expression profiling in multiple sclerosis

Project description:We measured global mRNA expression in peripheral blood mononuclear cells (PBMC) from 182 individuals, comprising of 142 multiple sclerosis (MS) patients affected with distinct MS clinical forms and 40 healthy controls.

2017-09-30 | E-MTAB-4890 | biostudies-arrayexpress

Peripheral blood gene expression profiling in multiple sclerosis

Project description:We measured global mRNA expression in peripheral blood mononuclear cells (PBMC) from 76 individuals, comprising of 49 multiple sclerosis (MS) patients affected with distinct MS clinical forms and 27 healthy controls.

2017-09-30 | E-MTAB-5151 | biostudies-arrayexpress

Transcription signature of Multiple Sclerosis in peripheral blood mononuclear cells.

Project description:Background: pregnancy is associated with reduced activity of multiple sclerosis (MS). However, the biological mechanisms underlying this pregnancy-related decrease in disease activity are poorly understood. This data series contains the subset of data used to generate a MS signature comparing female healthy specimens with respect to MS patients

2010-01-10 | GSE17393 | GEO

Design of an unbiased machine learning workflow to predict Multiple Sclerosis staging from blood transcriptome

Project description:Construction of gene expression-based classifiers to predict the different Multiple Sclerosis stages from peripheral blood mononuclear cells (PBMC) transcriptome of MS patients and controls.

2020-09-01 | GSE136411 | GEO

Disease modifying therapy impacts on miRNA expression profiling in peripheral blood from Relapsing-Remitting Multiple Sclerosis patients

Project description:Multiple sclerosis (MS) is a chronic and progressive neurological disease. MS is characterized by early-stage neuroinflammation, neurodegeneration, and demyelination, with a spectrum of heterogeneous clinical manifestations in terms of disease course and response to therapy. The currently unsatisfied availability of diagnostic and prognostic biomarkers concerning disease progression and treatment response represents an important requirement for therapy individualization and drug efficacy. Specific Disease Therapies (DMTs) are available to prevent MS-related brain damage; however, the specific drug choice is still under debate and needs further characterization. Since differentially expressed miRNAs have been proposed as diagnostic tools in neurodegenerative/neuro-inflammatory diseases, such as multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease, we characterized the miRNA expression profiling in peripheral blood mononuclear cells (PBMC) of subjects with relapsing-remitting MS treated with high efficacy DMTs: Cladribine (CLA, n=11 patients) or Ocrelizumab (OCRE, n=14 patients). The treated patients were compared to control (CTR) untreated subjects (n=15). Blood samples were collected from patients before treatment (time t0) and 6 months post-treatment (time t1), but just once from control subjects. CLA drug tablets were administered to the selected relapsing-remitting MS patients with a dosage of 1.75 mg/kg given for 5 days. OCRE drug was administered to the other relapsing-remitting MS patients by infusion with a dosage of 300 mg, twice in two weeks.

2024-01-03 | GSE230064 | GEO

Identification of early neurodegenerative pathways in progressive multiple sclerosis

Project description:Identification of early neurodegenerative pathways in progressive multiple sclerosis

| PRJNA730884 | ENA